Advertisement
U.S. markets closed

Adynxx, Inc. (ADYX)

Other OTC - Other OTC Delayed Price. Currency in USD
0.00000.0000 (0.00%)
At close: 09:31AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0000
Open0.0000
Bid0.0000 x 800
Ask0.0000 x 1300
Day's Range0.0000 - 0.0000
52 Week Range0.0000 - 0.0003
Volume14
Avg. Volume0
Market Cap871
Beta (5Y Monthly)2.14
PE Ratio (TTM)N/A
EPS (TTM)-0.0300
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMay 06, 2019
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ADYX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ADYNXX INC
    Analyst Report: Medtronic plcOne of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
    Rating
    Fair Value
    Economic Moat
    11 days agoMorningstar
View more
  • GlobeNewswire

    NEXGEL to Report First Quarter 2023 Financial Results on May 15th

    Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the first quarter ended March 31, 2023, after the market closes on May 15, 2023. Following the release of its financial and operating results, the Co

  • GlobeNewswire

    NEXGEL Reports Fourth Quarter and Full Year 2022 Financial Results

    2022 revenue increased 32% YoY to $2.05 million, while gross profit margin improved As of December 31, 2022, had over $6.6 million in cash and securities which is sufficient to operate through 2025 LANGHORNE, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced financial results for the fourth quarter and full year ended

  • GlobeNewswire

    NEXGEL to Report Fourth Quarter and Full Year 2022 Financial Results on March 27th

    Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., March 15, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the fourth quarter and full year periods ended December 31, 2022, after the market closes on March 27, 2023. Following the release of its financial